Brind.
  1. The FDA accepted the BLA submission for Tabelecleucel and granted Priority Review, with Pierre Fabre Pharmaceuticals Inc. preparing for approval.

Atara Biotherapeutics partnered with Pierre Fabre Pharmaceuticals, which is currently seeking regulatory approval for its products.

2 reports, 2 independent Updated Oct 14
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Atara Biotherapeutics partnered with Pierre Fabre Pharmaceuticals, which is currently seeking regulatory approval for its products.

Who's involved

What this event is mainly about
Atara Biotherapeutics, Inc.

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA acceptance moves the drug closer to U.S. launch, following approvals from the EC and Switzerland.1 source
  2. Atara transferred IND to Pierre Fabre, which is preparing for regulatory approval.1 source

Keep exploring

Part of

The FDA accepted the BLA submission for Tabelecleucel and granted Priority Review, with Pierre Fabre Pharmaceuticals Inc. preparing for approval. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • pacbiztimes.com
  • PR NewswirePerre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. Pierre Fabre Laboratories is now responsible for all gl